Student Research Committee, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Pharmaceutical Sciences Research Center, Hemoglobinopathy Institute, Mazandaran University of Medical Sciences, Sari, Iran.
AAPS PharmSciTech. 2024 Sep 12;25(7):213. doi: 10.1208/s12249-024-02906-7.
To overcome the challenges associated with the co-delivery of AuNPs (gold nanoparticles) and miRNA as an anti-breast cancer combination therapy, niosomal systems were developed using Span 60, cholesterol, and a cationic lipid (CTAB), and the formulations were optimized using Box-Behnken experimental design. The niosomal formulations with the smallest size were selected for further optimization of size, surface charge, entrapment efficiency, and stability. To achieve this, AuNPs and DSPE-PEG2000 (2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene glycol)-2000)were added to the formulation. The optimized niosomal formulation could effectively encapsulate AuNPs with an entrapment efficiency of 34.49% ± 0.84 and a spherical particle size of 153.6 ± 4.62 nm. The incorporation of PEG and CTAB led to notable enhancements in the overall characteristics of the delivery system. To evaluate the effectiveness of the combination therapy, various assessments such as cytotoxicity, apoptosis, and gene expression properties were conducted. The results demonstrated that the combination delivery using the new C-PEG-Nio-AuNPs (cationic pegylated niosomal gold nanoparticles) system and miRNA had the lowest IC50, the highest apoptosis rate, and the most significant upregulation of miRNA and BAX/BCL2 expression in MCF-7 cell growth. In conclusion, this innovative co-delivery approach represents a promising breakthrough in the development of therapeutic agents for breast cancer treatment. By combining multiple therapeutic agents within a single delivery system, this method has the potential to enhance treatment efficacy, reduce side effects, and improve patient outcomes.
为了克服共递送 AuNPs（金纳米颗粒）和 miRNA 作为抗乳腺癌联合治疗的挑战，使用 Span 60、胆固醇和阳离子脂质（CTAB）开发了非离子囊泡系统，并使用 Box-Behnken 实验设计优化了配方。选择具有最小粒径的非离子囊泡配方进一步优化粒径、表面电荷、包封效率和稳定性。为此，向配方中添加了 AuNPs 和 DSPE-PEG2000（2-硬脂酰-sn-甘油-3-磷酸乙醇胺-N-[氨基（聚乙二醇）-2000]。优化的非离子囊泡配方能够有效地包封 AuNPs，包封效率为 34.49%±0.84，粒径为 153.6±4.62nm。PEG 和 CTAB 的加入显著增强了递药系统的整体特性。为了评估联合治疗的有效性，进行了细胞毒性、细胞凋亡和基因表达特性等各种评估。结果表明，使用新的 C-PEG-Nio-AuNPs（阳离子化聚乙二醇化非离子囊泡金纳米颗粒）系统和 miRNA 的联合递药具有最低的 IC50、最高的凋亡率以及对 MCF-7 细胞生长中 miRNA 和 BAX/BCL2 表达的最显著上调。总之，这种创新的共递药方法代表了治疗乳腺癌的治疗剂开发方面的一个有前途的突破。通过将多种治疗剂组合在单个递药系统中，这种方法有可能增强治疗效果、降低副作用并改善患者的治疗效果。
